Honigman Advises BioXcel Therapeutics on $14 Million Registered Direct Offering

BioXcel Therapeutics, Inc., a biopharmaceutical company, closed on March 4, 2025 its registered direct offering of (i) 4,000,000 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 4,000,000 shares of common stock and (ii) warrants, exercisable for two weeks after the closing of the offering, to purchase up to an additional 4,000,000 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 4,000,000 shares of common stock, at a combined offering price of $3.50 per share or pre-funded warrant. Gross proceeds from the offering were approximately $14 million, before deducting discounts and commissions and offering expenses.

Honigman advised BioXcel Therapeutics, Inc. in the offering and was led by corporate partners N. Danny Shulman and Emily J. Johns, with associates Isaac Pasha and Cassie J. O'Hagan.